Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Type 2 (T2DM) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)

NCT05579314
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
XW014, Placebo
Drug
Lead sponsor
Sciwind Biosciences USA Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 11, 2026, 10:12 PM EDT
Recruiting Not applicable Interventional

OASIS: Peer Support for T2DM in Appalachia (Peer Coaches)

NCT06003634
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Peer Coaching - Peer Participants A, Peer Coaching - Peer Participants B, Peer Coaching - Peer Participants C, Peer Coaching - Peer Participants D
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bowling Green, Kentucky • Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 11, 2026, 10:12 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Evaluation of a Nutritional Supplement for People With Type 2 Diabetes.

NCT01850134
View directory record Official record
Conditions
Diabetes
Interventions
Experimental Study Product, Control Study Product
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Addison, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Preventing T2DM After GDM With Immediate Postpartum Screening

NCT06457139
View directory record Official record
Conditions
Gestational Diabetes, Type 2 Diabetes
Interventions
Glucose tolerance test (2 hour), Active Comparator
Diagnostic Test · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Phase 4 Interventional

"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

NCT00402012
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

NCT07321678
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
ASC30 tablets, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Riverside, California • San Jose, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

NCT01517373
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Roseville, California • San Diego, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Early Phase 1 Interventional

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

NCT05093517
View directory record Official record
Conditions
Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
Interventions
REMD-477, Placebo Subcutaneous injection
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 11, 2026, 10:12 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

NCT07160257
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Nutritional Product for People With Type 2 Diabetes

NCT01850810
View directory record Official record
Conditions
Diabetes
Interventions
Experimental Study Product, Control Study Product
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

NCT05232071
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Interventions
Lanifibranor, Placebo, Empagliflozin
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

NCT02058147
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
118
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 11, 2026, 10:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM).

NCT00361946
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Effects of a Plant-Based Diet on Insulin Requirements and Obesity Markers in Obese Adults With T2DM

NCT04048642
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Obesity, Nutritional and Metabolic Disease
Interventions
DASH, Whole-Food, Plant-Based
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Webster, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 11, 2026, 10:12 PM EDT
Not listed No phase listed Observational

CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery

NCT05666479
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Interventions
Dexcom G6 Pro Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED

NCT06899191
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Hyperglycemia, Insulin Dependent Diabetes
Interventions
Hemoglobin A1c, Observation Unit
Diagnostic Test · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Effectiveness of and Implementation Strategies for 'Disfrutando'.

NCT07023406
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Disfrutando
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Columbia, Missouri • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 11, 2026, 10:12 PM EDT
Completed No phase listed Observational

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

NCT03090464
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Use of digital disease management tool
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Birmingham, Alabama • Peoria, Arizona • Surprise, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Targeting Hyaluronan Accumulation Through Exercise in T2DM

NCT04383314
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
10-week exercise program on HA accumulation
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

NCT02025907
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Not applicable Interventional Results available

Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM

NCT00929838
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions
Diabetes Knowledge/Information, Motivation/Behavioral Skills, Combined Intervention, Usual Care
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 11, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

NCT01129258
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Oct 11, 2026, 10:12 PM EDT
Terminated Not applicable Interventional

Building Self-regulation Capacity in AA T2DM Women: Feasibility of EMI

NCT04083248
View directory record Official record
Conditions
Type 2 Diabetes, Self-regulation
Interventions
Feasibility group
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 11, 2026, 10:12 PM EDT